341 related articles for article (PubMed ID: 26109433)
1. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.
Riz I; Hawley TS; Hawley RG
Oncotarget; 2015 Jun; 6(17):14814-31. PubMed ID: 26109433
[TBL] [Abstract][Full Text] [Related]
2. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
3. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Riz I; Hawley TS; Marsal JW; Hawley RG
Oncotarget; 2016 Oct; 7(41):66360-66385. PubMed ID: 27626179
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
Jarauta V; Jaime P; Gonzalo O; de Miguel D; Ramírez-Labrada A; Martínez-Lostao L; Anel A; Pardo J; Marzo I; Naval J
Cancer Lett; 2016 Nov; 382(1):1-10. PubMed ID: 27565383
[TBL] [Abstract][Full Text] [Related]
6. Chloroquine blocks the autophagic process in cisplatin-resistant osteosarcoma cells by regulating the expression of p62/SQSTM1.
Shen C; Wang W; Tao L; Liu B; Yang Z; Tao H
Int J Mol Med; 2013 Aug; 32(2):448-56. PubMed ID: 23722646
[TBL] [Abstract][Full Text] [Related]
7. Involvement of selective autophagy mediated by p62/SQSTM1 in KLHL3-dependent WNK4 degradation.
Mori Y; Mori T; Wakabayashi M; Yoshizaki Y; Zeniya M; Sohara E; Rai T; Uchida S
Biochem J; 2015 Nov; 472(1):33-41. PubMed ID: 26349538
[TBL] [Abstract][Full Text] [Related]
8. Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.
Sha Z; Schnell HM; Ruoff K; Goldberg A
J Cell Biol; 2018 May; 217(5):1757-1776. PubMed ID: 29535191
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62.
Myeku N; Figueiredo-Pereira ME
J Biol Chem; 2011 Jun; 286(25):22426-40. PubMed ID: 21536669
[TBL] [Abstract][Full Text] [Related]
10. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
11. The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
Rui YN; Xu Z; Chen Z; Zhang S
Autophagy; 2015; 11(5):812-32. PubMed ID: 25984893
[TBL] [Abstract][Full Text] [Related]
12. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.
Yu H; Su J; Xu Y; Kang J; Li H; Zhang L; Yi H; Xiang X; Liu F; Sun L
Eur J Cancer; 2011 Jul; 47(10):1585-94. PubMed ID: 21371883
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
Puissant A; Robert G; Fenouille N; Luciano F; Cassuto JP; Raynaud S; Auberger P
Cancer Res; 2010 Feb; 70(3):1042-52. PubMed ID: 20103647
[TBL] [Abstract][Full Text] [Related]
14. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
15. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
16. Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells.
Viiri J; Amadio M; Marchesi N; Hyttinen JM; Kivinen N; Sironen R; Rilla K; Akhtar S; Provenzani A; D'Agostino VG; Govoni S; Pascale A; Agostini H; Petrovski G; Salminen A; Kaarniranta K
PLoS One; 2013; 8(7):e69563. PubMed ID: 23922739
[TBL] [Abstract][Full Text] [Related]
17. SQSTM1/p62-mediated autophagy compensates for loss of proteasome polyubiquitin recruiting capacity.
Demishtein A; Fraiberg M; Berko D; Tirosh B; Elazar Z; Navon A
Autophagy; 2017 Oct; 13(10):1697-1708. PubMed ID: 28792301
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Nabissi M; Morelli MB; Offidani M; Amantini C; Gentili S; Soriani A; Cardinali C; Leoni P; Santoni G
Oncotarget; 2016 Nov; 7(47):77543-77557. PubMed ID: 27769052
[TBL] [Abstract][Full Text] [Related]
19. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.
Hawley TS; Riz I; Yang W; Wakabayashi Y; Depalma L; Chang YT; Peng W; Zhu J; Hawley RG
Am J Hematol; 2013 Apr; 88(4):265-72. PubMed ID: 23475625
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
Clin Cancer Res; 2012 Oct; 18(20):5639-49. PubMed ID: 22929803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
